NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kernal Biologics

Kernal Biologics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://kernalbio.com/

Last Round

Grant

Oct 7, 2025

Total Funding Raised

$25M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kernal Biologics is a biotechnology company that develops mRNA-based immunotherapies for cancer and autoimmune diseases using AI-designed, cell-selective mRNA and targeted lipid nanoparticle technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

mRNA therapeuticsmRNA designin vivo CAR-Tsolid tumor therapycomputational biologylarge language modelLLMdrug discoveryprecision medicinebiotech platformAI drug discoverymRNA 2.0biotech licensingAI for biologybio-pharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kernal Biologics Comparables

Compare Kernal Biologics with similar companies based on industry and business-model similarity.

Kernal Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RNAimmune
82%
Strand Therapeutics
81%
Myeloid Therapeutics
80%

Kernal Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 7, 2025
Series AJul 7, 2022

Kernal Biologics Investors

Notable investors and investment history

Kernal Biologics investors
InvestorRounds
HBM Healthcare InvestmentsSeries A
Amgen VenturesSeries A
ARPA-HGrant
Civilization VenturesSeries A
Hummingbird VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Grew 19% QoQ, from 16 to 19 employees.

  • Oct 8, 2025

    KR-402 is in development for B cell cancers.

Kernal Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kernal Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kernal Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range23
Year Founded2016
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.